Loading...

Novartis AG
SIX:NOVN

Watchlist Manager
Novartis AG Logo
Novartis AG
SIX:NOVN
Watchlist
Price: 79.39 CHF -0.19% Market Closed
Updated: Feb 6, 2023

Intrinsic Value

The intrinsic value of one NOVN stock under the Base Case scenario is 80.15 CHF. Compared to the current market price of 79.39 CHF, Novartis AG is Undervalued by 1%.

The Intrinsic Value is calculated as the average of the two valuation methods:

NOVN Intrinsic Value
Base Case
80.15 CHF
Undervaluation 1%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Fundamental Analysis

NOVN Profitability Score
Profitability Due Diligence

Novartis AG's profitability score is 67/100. The higher the profitability score, the more profitable the company is.

Positive 3-Year Average ROIC
Negative 1-Year Revenue Growth
Positive Revenue Growth Forecast
Positive ROIC
67/100
Profitability
Score

Novartis AG's profitability score is 67/100. The higher the profitability score, the more profitable the company is.

NOVN Solvency Score
Solvency Due Diligence

Novartis AG's solvency score is 71/100. The higher the solvency score, the more solvent the company is.

Short-Term Liabilities
Positive Net Debt
High Altman Z-Score
Long-Term Liabilities
71/100
Solvency
Score

Novartis AG's solvency score is 71/100. The higher the solvency score, the more solvent the company is.

Financials
Efficiency
71%
Gross Margin
24%
Operating Margin
42%
Net Margin
21%
FCF Margin
37%
ROE
12%
ROIC
Other

NOVN Capital Structure
Novartis AG

Market Capitalization 171B CHF
Total Debt 21.2B CHF
Minority Interest 78M CHF
Preferred Equity 0 CHF
Cash and Equivalents 8.7B CHF
Short-Term Investments 10.4B CHF
Enterprise Value 173B CHF

Wall St
Price Targets

NOVN Price Targets Summary
Novartis AG

Wall Street analysts forecast NOVN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NOVN is 91.5 CHF with a low forecast of 70.7 CHF and a high forecast of 111.3 CHF.

Lowest
Price Target
70.7 CHF
11% Downside
Average
Price Target
91.5 CHF
15% Upside
Highest
Price Target
111.3 CHF
40% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

NOVN Competitors
Novartis AG

NOVN Suppliers & Customers
Novartis AG

Novartis AG has 114 key suppliers from 12 countries and 19 industries. The majority of these suppliers are located in the United States of America, with the largest number of suppliers in the Biotechnology industry.

United States of America
58
Veeva Systems Inc
Health Care
D
DoubleVerify Holdings Inc
Technology
Model N Inc
Technology
Hewlett Packard Enterprise Co
Technology
Catalent Inc
Pharmaceuticals
Invitae Corp
Health Care
Alexandria Real Estate Equities Inc
Real Estate
Graphic Packaging Holding Co
Packaging
Abbott Laboratories
Health Care
Snowflake Inc.
Technology
Cryoport Inc
Health Care
Gilead Sciences Inc
Biotechnology
Ligand Pharmaceuticals Inc
Biotechnology
Homology Medicines Inc
Biotechnology
OpGen Inc
Biotechnology
Voyager Therapeutics Inc
Biotechnology
Alnylam Pharmaceuticals Inc
Biotechnology
R
Royalty Pharma PLC
Pharmaceuticals
V
Viant Technology Inc
Technology
9
908 Devices Inc.
Electrical Equipment
Pliant Therapeutics Inc
Pharmaceuticals
T
TScan Therapeutics Inc
Biotechnology
D
Definitive Healthcare Corp
Health Care
Regenxbio Inc
Biotechnology
I
IDEAYA Biosciences Inc
Biotechnology
Incyte Corp
Biotechnology
Alphabet Inc
Media
Surface Oncology Inc
Biotechnology
X
Xencor Inc
Biotechnology
Kura Oncology Inc
Biotechnology
Certara Inc
Health Care
O
Organogenesis Holdings Inc
Biotechnology
Vanda Pharmaceuticals Inc
Biotechnology
Mirati Therapeutics Inc
Biotechnology
Pegasystems Inc
Technology
Iovance Biotherapeutics Inc
Biotechnology
Paratek Pharmaceuticals Inc
Pharmaceuticals
American Software Inc
Technology
A
Arteris Inc
Technology
Sangamo Therapeutics Inc
Biotechnology
Olema Pharmaceuticals Inc
Biotechnology
Myriad Genetics Inc
Biotechnology
Codexis Inc
Life Sciences Tools & Services
X
XOMA Corp
Biotechnology
Harvard Bioscience Inc
Life Sciences Tools & Services
Ionis Pharmaceuticals Inc
Biotechnology
ImmunoGen Inc
Biotechnology
Microsoft Corp
Technology
Sotherly Hotels Inc
Real Estate
Intellia Therapeutics Inc
Biotechnology
Liquidia Corp
Pharmaceuticals
Ayala Pharmaceuticals Inc
Biotechnology
Arrowhead Pharmaceuticals Inc
Biotechnology
Amazon.com Inc
Retail
OPTIMIZERx Corp
Health Care
BridgeBio Pharma Inc
Biotechnology
A
Apeiron Capital Investment Corp
N/A
S
Societal CDMO Inc
Pharmaceuticals
Suppliers Map

Novartis AG has 45 key customers from 9 countries and 8 industries. The majority of these customers are located in the United States of America, with the largest number of customers in the Biotechnology industry.

Customers Map

Shareholder Return

NOVN Price
Novartis AG

1M 1M
-7%
6M 6M
-4%
1Y 1Y
-1%
3Y 3Y
-16%
5Y 5Y
+14%
Annual Price Range
79.39
52w Low
73.98
52w High
87.82
Price Metrics
Average Annual Return 4.32%
Standard Deviation of Annual Returns 14.86%
Max Drawdown -27%
Shares Statistics
Market Capitalization 171B CHF
Shares Outstanding 2 204 239 028
Percentage of Shares Shorted
N/A

Company Profile

Novartis AG

Country

Switzerland

Industry

Pharmaceuticals

Market Cap

171B CHF

Dividend Yield

3.87%

Description

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. The company is headquartered in Basel, Basel-Stadt and currently employs 104,323 full-time employees. The company went IPO on 2001-05-07. The firm develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The firm uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.

Contact

BASEL-STADT
Basel
Lichtstrasse 35
+41613241111.0
https://www.novartis.com/

IPO

2001-05-07

Employees

104 323

Officers

Chief Exec. Officer
Dr. Vasant Narasimhan
Chief Financial Officer
Mr. Harry Kirsch
Chief Ethics, Risk & Compliance Officer
Dr. Klaus Moosmayer Ph.D.
Chief Legal Officer
Ms. Karen L. Hale
Chief People & Organization Officer
Dr. Robert Kowalski Pharm.D.
Pres of Operations
Mr. Steffen Lang Ph.D.
Show More
Pres of Innovative Medicines International & Chief Commercial Officer
Ms. Marie-France Tschudin
Chief Exec. Officer of Sandoz
Mr. Richard Saynor
Head of Group Financial Reporting and Accounting
Paul Penepent
Global Head of Investor Relations
Dr. Samir Shah M.D.
Show Less

See Also

Similar Stocks
What is the Intrinsic Value of one NOVN stock?

The intrinsic value of one NOVN stock under the Base Case scenario is 80.15 CHF.

Is NOVN stock undervalued or overvalued?

Compared to the current market price of 79.39 CHF, Novartis AG is Undervalued by 1%.